Category: Lung Cancer in Focus
Chemotherapy and Immunotherapy in Early-Stage NSCLC: Neoadjuvant vs Adjuvant Therapy
H&O Which patients with early-stage non–small cell lung cancer (NSCLC) are eligible for surgical resection? HW We perform surgical resection in nearly all patients with stage […]
Updates in Small Cell Lung Cancer
H&O How common is small cell lung cancer (SCLC), and who is at risk? JS Lung cancer is the second most common cancer type in men […]
The Use of Biomarkers in Early-Stage NSCLC
H&O Should patients with early-stage non–small cell lung cancer (NSCLC) get biomarker testing of their surgical specimens? JK A few years ago, I would have said […]
Advances in Immune Checkpoint Inhibition for Patients With Lung Cancer
H&O What are the newest indications for checkpoint inhibitors in lung cancer? HB The newest indication in the neoadjuvant setting is the use of nivolumab (Opdivo, […]
Novel Targets in Advanced Non–Small Cell Lung Cancer
H&O Which targeted agents are approved for use in patients with advanced non–small cell lung cancer (NSCLC)? SL We are blessed with an embarrassment of riches […]
The Next Targets for Small Cell Lung Cancer
H&O What are the goals of treatment in small cell lung cancer (SCLC)? RS Our ultimate goal is cure, but we know that SCLC is a […]
Immunotherapy for Small Cell Lung Cancer: Established Applications and Novel Approaches
Abstract: Small cell lung cancer (SCLC) is a devastating disease that has a case fatality rate of more than 90% despite best available treatments. As a […]
Neoadjuvant and Adjuvant Approaches in Surgically Resectable NSCLC
H&O Which patients with non–small cell lung cancer (NSCLC) are eligible for surgical resection? JC Surgical resectability, which is determined by the thoracic surgeon, is based […]
Stereotactic Body Radiation Therapy in Advanced NSCLC
H&O What is the standard first-line treatment in advanced non–small cell lung cancer (NSCLC)? TW The standard treatment for unresectable, locally advanced stage III NSCLC is […]
What’s Next for Immunotherapy in Locally Advanced NSCLC?
H&O Which immunotherapy agents have been approved for use in locally advanced non–small cell lung cancer? NR Durvalumab (Imfinzi, AstraZeneca) is the only agent to have […]
Lung Cancer News
Progression-Free Survival Longer With Lorlatinib Than With Crizotinib Progression-free survival (PFS) is longer with lorlatinib (Lorbrena, Pfizer) than with crizotinib (Xalkori, Pfizer) in advanced ALK-positive non–small […]
Emerging Role of Immunotherapy in Locally Advanced Non–Small Cell Lung Cancer
Abstract: Non–small cell lung cancer (NSCLC) accounts for 85% of the cases of lung cancer in the United States, and 70% of patients with NSCLC […]
Immunotherapy in Patients Who Have NSCLC Without EGFR or ALK Mutations
H&O What made you and your colleagues decide to undertake the KEYNOTE-189 trial? LG KEYNOTE-189 (Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab […]
Looking Ahead to New Therapies in Small Cell Lung Cancer
H&O How common is small cell lung cancer (SCLC)? CR Approximately 25,000 to 30,000 cases of SCLC occur each year in the United States, a number […]
ALK Inhibitors in Non–Small Cell Lung Cancer: How Many Are Needed and How Should They Be Sequenced?
H&O Which patients with non–small cell lung cancer (NSCLC) are candidates for treatment with crizotinib? AS Crizotinib (Xalkori, Pfizer) is a multitargeted tyrosine kinase inhibitor […]
How I Treat Stage IV Non–Small Cell Lung Cancer in the Absence of Any Actionable Oncogenic Driver
Overview • Testing for several genetic alterations as well as programmed death ligand 1 (PD-L1) expression is paramount in the management of advanced, metastatic non–small cell […]
The Next Frontier in Non–Small Cell Lung Cancer: Synergizing Radiation Therapy and Immune Checkpoint Blockade
Abstract: Immune checkpoint blockade (ICB), which harnesses the body’s immune system to recognize and kill cancer cells, has transformed the management landscape for patients with […]
Does Plasma-Based Molecular Testing Have a Role in the Routine Care of Lung Cancer?
H&O What is the gold standard method for detecting genetic mutations in patients with lung cancer? HW The gold standard for detecting genetic mutations remains […]
Programmed Death Ligand 1 Testing: Is There One Best Test?
H&O Is programmed death ligand 1 (PD-L1) testing always done before prescribing a programmed death 1 (PD-1)/PD-L1 inhibitor in patients with non–small cell lung cancer […]
Optimal Treatment of Unresectable Stage III Non–Small Cell Lung Cancer
Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 Jeffrey D. Bradley, MD S. Lee Kling Professor of Radiation Oncology Alvin J. Siteman […]